India's first indigenous mRNA vax Gemcovac-19 likely to be available soon

Gennova Biopharmaceuticals Ltd aims to produce around 4 - 5 million doses per month and this capacity can be quickly doubled

Gennova
Premium

Gennova Biopharmaceuticals

Sohini Das Mumbai
Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals, announced that its mRNA vaccine - Gemcovac-19 - against Covid-19 received the Emergency Use Authorization (EUA) from the office of the Drugs Controller General of India (DCGI).

Gemcovac-19 is the very first mRNA vaccine developed in India and only third mRNA vaccine to be approved for COVID-19 in the world.

Gennova Biopharmaceuticals Ltd aims to produce around 4 - 5 million doses per month and this capacity can be quickly doubled.

First Published: Jun 29 2022 | 1:26 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com